Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data
With More Than 100% Upside Seen In Idera Pharma Shares, Baird Initiates At Outperform
The Next Steps For Ultragenyx' Burosumab Following Positive Phase 3 Data
Amicus Therapeutics Upgraded To Outperform; Overhangs Are Removed With Catalysts Ahead